14 Feb 2026 • The World Health Organization (WHO) has prequalified an additional novel oral polio vaccine type 2 (nOPV2). The prequalification designation indicates that the vaccine meets international standards of quality, safety, and efficacy for global immunization programmes.

nOPV2 is indicated for active immunization in all age groups and is authorized for emergency use in response to outbreaks caused by poliovirus type 2, when and where required by the Global Polio Eradication Initiative (GPEI) or WHO.

The World Health Organization (WHO) has prequalified an additional novel oral polio vaccine type 2 (nOPV2), further strengthening the global supply of a vaccine at the heart of efforts to stop poliovirus type 2 outbreaks more sustainably and accelerate progress towards polio eradication.

The prequalification designation indicates that the vaccine meets international standards of quality, safety, and efficacy for global immunization programmes. It enables the vaccine to be purchased and supplied through United Nations procurement agencies, including UNICEF, supporting its use across multiple country settings for the prevention and control of poliovirus transmission.

The newly prequalified product is manufactured by Biological E. Limited (BioE), India, using in-house bulk vaccine following a technology transfer from PT Bio Farma (Persero), Indonesia.

Source: WHO | Read full story